

1 **Recent SARS-CoV-2 seroconversion in a national, community-based**
2 **prospective cohort of U.S. adults**

3 **Authors:** Denis Nash^{1,2*}, Madhura Rane¹, Mindy Chang¹, Sarah Gorrell Kulkarni¹, Rebecca
4 Zimba¹, William You¹, Amanda Berry¹, Chloe Mirzayi^{1,2}, Shivani Kochhar¹, Andrew Maroko^{1,3},
5 McKaylee M. Robertson¹, Drew Westmoreland¹, Angela Parcesepe^{1,4,5}, Levi Waldron^{1,2}, and
6 Christian Grov^{1,6}

7 **Affiliations:**

8 ¹Institute for Implementation Science in Population Health (ISPH), City University of
9 New York (CUNY); New York City, New York USA

10 ²Department of Epidemiology and Biostatistics, Graduate School of Public Health and
11 Health Policy, City University of New York (CUNY); New York City, New York
12 USA

13 ³Department of Environmental, Occupational, and Geospatial Health Sciences, Graduate
14 School of Public Health and Health Policy, City University of New York (CUNY);
15 New York City, New York USA

16 ⁴Department of Maternal and Child Health, Gillings School of Public Health, University
17 of North Carolina, Chapel Hill, NC, USA

18 ⁵Carolina Population Center, University of North Carolina at Chapel Hill, Chapel Hill,
19 NC, USA

20 ⁶Department of Community Health and Social Sciences, Graduate School of Public
21 Health and Health Policy, City University of New York (CUNY); New York City,
22 New York USA

23
24 ***CORRESPONDING AUTHOR:**

25 Denis Nash, Ph.D., MPH

26 City University of New York (CUNY) Graduate School of Public Health and Health Policy
27 55 W. 125th St., 6th Floor
28 New York, NY USA 10027

29 Email: denis.nash@sph.cuny.edu

30 Twitter: @epi_dude

31 SHORT ABSTRACT

32 Epidemiologic risk factors for incident SARS-CoV-2 infection are best characterized via
33 prospective cohort studies, complementing case-based surveillance and cross-sectional
34 seroprevalence studies. In March 2020, we launched the CHASING COVID Cohort Study, a
35 national, community-based prospective cohort study of 6,745 U.S. adults who underwent at-
36 home specimen collection for repeat serologic testing for SARS-CoV-2 antibodies. We identify
37 and quantify several policy-sensitive risk factors for recent SARS-CoV-2 seroconversion,
38 highlight persistent racial/ethnic disparities in incidence, document continued elevated risk
39 among essential workers, and call attention to major gaps in the coverage of public health
40 interventions aimed at testing, isolation, and contact tracing. We conclude that modifiable risk
41 factors and poor reach of public health strategies drive SARS-CoV-2 transmission and inequities
42 across the U.S.

43

44 LONG ABSTRACT

45 Background

46 Epidemiologic risk factors for incident SARS-CoV-2 infection are best characterized via
47 prospective cohort studies, complementing case-based surveillance and cross-sectional
48 seroprevalence studies.

49

50 Methods

51 We estimated the cumulative incidence of SARS-CoV-2 infection and incidence rates of
52 seroconversion in a national prospective online cohort of 6,745 U.S. adults, enrolled March-July
53 2020. A subset (n=4,459) underwent serologic testing (Bio-Rad Platelia Total Ab,
54 IgA/IgM/IgG), offered initially May-September 2020 and again November 2020-January 2021.

55

56 Results

57 A total of 303 of 4,459 individuals showed serologic evidence of past SARS-CoV-2 infection
58 (cumulative incidence of 6.8%; 95% Confidence Interval [CI] 6.1%-7.6% [6.3%, 95% CI 5.7%-
59 7.1% adjusting for laboratory test error]). Among 3,280 initially seronegative participants with a
60 subsequent serologic test, we observed 145 seroconversions during 1,562 person years of follow-
61 up (incidence rate of 9.3 per 100 person-years [95% CI 17.9-11.0]). Racial/ethnic disparities in
62 crude incidence rates were apparent through January 2021 (rate ratio [RR]_{Hispanic vs Whites}=2.1;
63 95% CI 1.4-3.1; RR_{non-Hispanic Blacks vs Whites}=1.8; 95% CI 0.96-3.1). Incidence was higher in the
64 southern (RR_{South vs Northeast}=1.7; 95% CI 1.1-2.8) and midwestern (RR_{Midwest vs Northeast}=1.6; 95%
65 CI 0.98-2.7) regions, in rural vs urban areas (RR=1.5; 95% CI 1.0-2.2), and among essential
66 workers (RR=1.7; 95% CI 1.1-2.5). Household crowding (RR=1.6, 95% CI 1.1-2.3), dining
67 indoors at restaurants/bars (RR=2.0; 95% CI 1.4-2.8), visiting places of worship (RR=2.0; 95%
68 CI 1.3-2.9), wearing masks sometimes vs always while grocery shopping (RR=2.5; 95% CI 1.3-
69 4.4), indoor visits with people outside the household with masks (RR_{always mask vs no visit}=2.6; 95%
70 CI 1.6-4.4) and without masks (RR_{sometimes mask vs no visit}=3.5; 95% CI 2.7-5.7; RR_{never mask vs no}
71 visit=5.3; 95% CI 3.1-8.9); working indoors at a place of employment with masks (RR_{always mask vs}
72 no in-person=2.0, 95% CI 1.4-2.8) and without masks (RR_{sometimes mask vs no in-person}= 2.0, 95% CI 1.1-

73 3.5; $RR_{\text{never mask vs no in-person}}=3.7$, 95% CI 1.3-8.5); attending a salon or gym with masks (RR_{always}
74 $\text{mask vs no salon/gym}=1.7$ (95% CI 1.1-2.4), gathering indoors and outdoors in groups of ≥ 10 ($RR=1.9$,
75 95% CI 1.2-2.0); and air travel during the pandemic ($RR=1.7$; 95% CI 1.1-2.6) were also
76 associated with higher incidence rates. Among 303 seropositive individuals, 27.4% had
77 asymptomatic infection, and 32% reported a positive SARS-CoV-2 PCR test or provider
78 diagnosis of COVID-19. In this group, there were major gaps in the coverage of public health
79 interventions aimed at isolation (31% isolated) and contact tracing (asked about contacts [18%];
80 told about exposure to a confirmed case [7.6%]).

81

82 **Conclusions**

83 Modifiable risk factors and low reach of public health strategies drive SARS-CoV-2 transmission
84 across the U.S. It is critical to address inequities in incidence, reduce risk factors, and improve
85 the reach of public health strategies in the vaccine era.

86

87 **KEYWORDS:** COVID-19; serology, seroconversion, asymptomatic infection, physical
88 distancing; natural history study, epidemiologic study, essential workers, public health
89 interventions, community transmission

90

91

92 INTRODUCTION

93 As of this writing, about one year after the emergence of SARS-CoV-2 in the United States
94 (U.S.), there have been more than 25 million SARS-CoV-2 cases diagnosed, 435,000 deaths
95 recorded, and 23.5 million vaccine doses administered.¹ As compared to *diagnoses*, the true
96 number of *infections* to date in the U.S. is unknown, but national estimates in the general
97 population as measured by seroprevalence have put the cumulative incidence at 10% in
98 September 2020² and 14% as of November 2020.³ One recent study in a nationally
99 representative sample of U.S. adults found that 4.6% had a history of undiagnosed SARS-CoV-2
100 as of July 2020: about 5 undiagnosed infections for every diagnosed case.⁴

101 A major challenge of controlling community transmission of SARS-CoV-2 is that the virus'
102 infectious period allows for onward spread prior to recognition of infection, by the substantial
103 proportion of people with asymptomatic infection, and during the pre-symptomatic period among
104 those who go on to develop symptoms.^{4,5}

105 While SARS-CoV-2 is understood to be transmitted from person-to-person via droplet and
106 airborne spread, to date, the incidence of SARS-CoV-2 infection and risk factors for incident
107 infection have not been well-characterized by routine case-based surveillance of SARS-CoV-2
108 diagnoses or by cross-sectional seroprevalence studies.¹⁻³ As the pandemic progresses through
109 different seasons and stages, it is critical to continue to characterize COVID-19's evolving
110 epidemiology and risk factors for SARS-CoV-2 acquisition, the uptake and impact of non-
111 pharmaceutical interventions (NPIs)⁶, and the reach of public health strategies aimed at
112 controlling community transmission, including testing, quarantine, isolation, contact tracing, and
113 vaccination.

114 Researchers and public health practitioners have called for prospective cohort studies to
115 describe incidence rates and how they are influenced by NPI implementation and uptake,
116 sociodemographics, knowledge and behaviors, and other potential risk factors.⁷ Yet, both the
117 frequency with which many risk factors occur in community samples, as well as the SARS-CoV-
118 2 risk that could be attached to them, still have not been systematically assessed and
119 epidemiologically linked to outcomes like seroconversion. Globally, few prospective
120 epidemiologic studies of SARS-CoV-2 have been published to date. One recent global
121 systematic review of observational studies of SARS-CoV-2 that employed serologic or PCR
122 testing found 18 prospective studies.⁸ Most were focused on healthcare workers or other

123 occupational groups, individuals in congregate settings, evacuees, or cruise ships; none were
124 community-based (i.e., focused on risk factors in communities vs other higher risk
125 populations/settings).⁸ A greater understanding of SARS-CoV-2 incidence and risk factors in
126 community samples can substantially complement routine case-based surveillance of new SARS-
127 CoV-2 diagnoses and cross-sectional serosurveys, serving to inform aspects of implementation
128 of the public health response and policies.

129 In late March 2020, we launched the national, prospective Communities, Households and
130 SARS-CoV-2 Epidemiology (CHASING) COVID Cohort.⁹ We describe the cumulative
131 incidence of SARS-CoV-2 infection, risk factors for recent SARS-CoV-2 seroconversion, and,
132 for those with serologic evidence of prior SARS-CoV-2 infection, the reach and uptake of public
133 health strategies.

134

135 **METHODS**

136 We used internet-based strategies¹⁰⁻¹² to recruit a geographically and socio-demographically
137 diverse cohort of adults in the U.S. and U.S. territories into longitudinal follow-up with at-home
138 specimen collection. To be eligible for inclusion in the cohort, individuals had to: 1) reside in the
139 U.S. or a U.S. territory; 2) be aged 18 years or older; 3) provide a valid email address for follow-
140 up; and 4) demonstrate early engagement in study activities (provided a baseline specimen or
141 completed >1 recruitment/enrollment visits). Details of the study design and recruitment
142 procedures have been described previously.⁹

143

144 **Study measurements**

145 *Participant interviews.* Measures included on the cohort screening, enrollment and follow-up
146 questionnaires were derived from published research¹⁰, BRFSS¹³, 2009 H1N1 influenza
147 studies^{14,15}, and other COVID-19 studies.¹⁶ Measures were also developed *de novo*. Cohort
148 recruitment and enrollment visits were completed between March 28-August 21, 2020, during
149 which multiple rounds of interviews took place. Essential worker status was defined as working
150 in law enforcement, emergency management, delivery, transportation, construction or healthcare
151 at study enrollment. We separated healthcare workers from other essential workers and treated
152 them as distinct categories in our analyses. From follow-up interviews we obtained repeated

153 measurements of symptoms, testing, hospitalizations, quarantine, isolation, contact tracing
154 encounters, and other time-varying factors.

155 *At-home specimen collection for serologic testing.* As part of study assessments during
156 May-August 2020 (Period 1) and November 2020-January 2021 (Period 2), participants were
157 invited to participate in serologic testing using an at-home self-collected dried blood spot (DBS)
158 specimen collection kit. Consenting participants were mailed a specimen collection kit, which
159 included written instructions and a QR code for an instructional video. DBS cards were sent from
160 and returned to the study laboratory (Molecular Testing Laboratories [MTL], Vancouver,
161 Washington) via the U.S. Postal Service (self-addressed, stamped envelope containing a
162 biohazard bag™).

163 *Serologic testing.* All DBS specimens were tested by the study laboratory for total
164 antibodies (Total Ab) using the Bio-Rad Platelia test for IgA, IgM, and IgG which targets the
165 SARS-CoV-2 nucleocapsid protein (manufacturer sensitivity 98.0%, specificity 99.3%).¹⁷
166 Specimens that were reactive on the Total Ab test were tested further using the Euroimmun IgG
167 test which targets the SARS-CoV-2 spike protein (manufacturer sensitivity 100%; specificity
168 99%).¹⁷ Both assays received Emergency Use Authorization from the U.S. Food and Drug
169 Administration and were further validated for use with DBS by the study laboratory using
170 confirmed, true positive and negative patient specimens. In these local validations, both assays
171 were found to have 100% sensitivity and 100% specificity (MTL, personal communication).

172 *Cumulative incidence of SARS-CoV-2 infection.* Among participants who underwent
173 serologic testing, we estimated the cumulative incidence of SARS-CoV-2 as the proportion of
174 individuals with a positive Total Ab test in either of the two time periods (i.e., number of
175 participants ever-positive) divided by the total number of persons with one or more Total Ab
176 tests (i.e., number of participants ever tested). We adjusted cumulative incidence estimates for
177 laboratory test error as reported by the kit manufacturer. Crude cumulative incidence estimates
178 are presented alongside adjusted estimates in supplemental tables. Unless otherwise specified, all
179 cumulative incidence estimates presented are adjusted for laboratory test error using the
180 following formula¹⁸:

$$\text{Adjusted cumulative incidence} = \frac{\text{Crude cumulative incidence} + \text{Specificity} - 1}{\text{Sensitivity} + \text{Specificity} - 1}$$

182 *Observed SARS-CoV-2 seroconversion and seroreversion.* Among those individuals with
183 two Total Ab tests, an observed seroconversion was defined as a negative Total Ab test in Period
184 1 followed by a positive Total Ab test in Period 2. We estimated the rate of seroconversion per
185 100 person years of follow-up using the collection dates for each specimen. Person-time at risk
186 began at the time of dried blood spot sample collection for the first serologic test or date the lab
187 received the sample if collection date was missing. The seroconversion date was assigned as the
188 midpoint between the first and second sample collection dates. Observed seroreversion was
189 defined as a positive Total Ab test in Period 1 followed by a negative Total Ab test in Period 2.

190

191 **Statistical analysis**

192 Cumulative incidence estimates and 95% confidence intervals (95% CIs) were stratified by
193 enrollment characteristics and risk factors ascertained prior to specimen collection. Incidence
194 proportions (observed seroconversions) were also stratified by risk factors measured prior to the
195 date of specimen collection in Period 2. All data were cleaned and analyzed in R (version 4.0.3)
196 and SAS (V9.4). Data were geocoded based on a self-reported ZIP code, and maps were created
197 in ArcGIS 10.7. For categorical variables with missing data frequency <5%, we imputed missing
198 data for participants using the most common value among all participants for a given variable.

199

200 **Ethical Approval**

201 The study protocol was approved by the Institutional Review Board at the City University of
202 New York (CUNY) Graduate School for Public Health and Health Policy.

203

204 **RESULTS**

205 The characteristics of the cohort are shown in Table 1, which includes participants from all 50
206 U.S. states, the District of Columbia, Puerto Rico, and Guam (see Fig. S1). Of the 6,745
207 participants enrolled in the cohort, 4,459 (66%) had at least one serologic test (Table 1).
208 Compared with the entire cohort, those who underwent any serologic testing were older and
209 more likely to be non-Hispanic White, college educated, and less likely to be healthcare workers
210 or essential workers. 4,235 persons underwent serologic testing in Period 1, and 3,615 persons
211 tested in Period 2. A total of 3,339 persons tested at both time points, including 3,280 who were
212 seronegative on their antibody test in Period 1 and who could be followed prospectively for the

213 outcome of SARS-CoV-2 seroconversion based on their subsequent serologic test result in the
 214 study. Differences between those testing in Period 1 and Period 2 were negligible (Table S1).
 215 The median time between specimen collection dates for both serologic tests was 190 days (IQR
 216 152-201) (Figure S2).
 217

Table 1. Baseline characteristics and serologic testing of CHASING COVID Cohort Study participants


	All participants		Participants with one or more serologic test	
	N	%	N	%
Total	6,745	100%	4459	66%
Age*				
Median (IQR)	37 (29,51)		41 (31, 55)	
18-29	1804	26.75	861	19.3
30-39	1965	29.13	1246	27.9
40-49	1160	17.2	846	19.0
50-59	792	11.74	646	14.5
60+	1024	15.18	860	19.3
Gender				
Male	3047	45.17	1991	44.7
Female	3527	52.29	2337	52.4
Non-Binary/Transgender	171	2.54	131	2.9
Race/Ethnicity*				
White Non-Hispanic	3859	56.8	2953	66.3
Hispanic	1310	19.42	669	15.0
Black Non-Hispanic	851	12.62	369	8.3
Asian	439	6.51	283	6.3
Pacific Islander	36	0.53	18	0.4
Other	250	3.71	167	3.8
Education				
Less than high school	123	1.82	52	1.2
High school graduate	879	13.03	399	9.0
Some college	1889	28.01	1126	25.3

College graduate	3854	57.14	2882	64.6
Employment*				
Employed	4249	62.99	2741	61.5
Out of work	830	12.31	535	12.0
Homemaker	352	5.22	240	5.4
Student	610	9.04	362	8.1
Retired	704	10.44	581	13.0
Household income*				
Less than \$35,000	2180	32.32	1288	28.9
\$35-49,999	753	11.16	487	10.9
\$50-69,999	960	14.23	635	14.2
\$70-99,999	1058	15.69	734	16.5
\$100,000+	1794	26.6	1315	29.5
Setting*				
Urban	2974	44.09	1962	44.0
Suburban	1760	26.09	1143	25.6
Rural	2011	29.81	1354	30.4
Geographic region*				
Northeast	1882	27.9	1294	29.0
Midwest	1127	16.71	794	17.8
South	2103	31.18	1269	28.5
West	1625	24.09	1097	24.6
US Dependent Territories	8	0.12	5	0.1
Healthcare worker*				
No	5948	88.18	4042	90.7
Yes	797	11.82	417	9.4
Essential worker				
No	5601	83	3858	86.5
Yes	1144	17	601	13.5
Higher risk for severe COVID**				
No	3167	46.95	2074	46.5
Yes	3578	53.05	2385	53.5

*<5% of the data were missing for this variable and values for those with missing values were imputed by assigning the most common value for this variable


** >60 years old, or reported co-morbidity, or current smoker.

219 **Cumulative incidence since the beginning of the pandemic and potential risk factors**
 220 The crude and adjusted serology-based estimates of cumulative incidence of SARS-CoV-2
 221 infection through the end of observation (January 31, 2021) were 6.8% (95% CI 6.1%-7.6%) and
 222 6.3% (95% CI 5.5%-7.1%), respectively (Table S2). Cumulative incidence rates declined in
 223 dose-response fashion with increasing age, with substantially lower incidence in those aged 60
 224 years and older (Figure 1). Higher cumulative incidence estimates were observed among males
 225 (7.8%, 95% CI 6.6%-9.0%), Hispanics 10.2% (95% CI 7.8%-12.6%), non-Hispanic Blacks
 226 (7.9%, 95% CI 5%-10.8%), those with a high school education (9.1%, 95% CI 0.9-20.9) or less
 227 (8.0%, 95% CI 5.2-10.9%), and those in the Northeast (7.8%, 95% CI 6.3%-9.4%). Lower
 228 cumulative incidence estimates were observed among persons aged 60 years and over (3.8%,
 229 95% CI 2.5%-5.2%), those whose gender identity was non-binary (2.5%, 95% CI 0.4%-5.5%),
 230 and those who were retired (3.4%, 95% CI 1.7%-4.9%).
 231



232
 233 **Figure 1** shows cumulative incidence estimates and 95% confidence intervals (CIs) for SARS-CoV-2 by baseline demographic characteristics of
 234 CHASING COVID Cohort Study participants. Estimates are adjusted for laboratory test error. Essential workers include people working in in law
 235 enforcement, emergency management, delivery, transportation, and construction. High risk group is defined as participants who either reported a
 236 comorbidity, were over 60 years old, or were a smoker. The size of the square box/marker is proportional to the overall sample size in each group.
 237

238 The estimated cumulative incidence of SARS-CoV-2 infection by epidemiologic risk factors
 239 reported at enrollment are shown in Figure 2 (and in Table S3). Higher cumulative incidence
 240 estimates were observed among those who, at cohort enrollment, reported having attended mass
 241 gatherings (8.6%, 95% CI 5.8%-12.4%), and lived in more crowded households (8.7%, 95% CI
 242 5.7%-13.2%). Those who thought they had COVID-19 in the past, and in Period 2, those who
 243 had a known SARS-CoV-2 exposure, sought a test, had a self-reported SARS-CoV-2 diagnosis
 244 or COVID-19-related hospitalization also had markedly higher cumulative incidence (Table S3).
 245 People living with HIV had the highest cumulative incidence among those with comorbidities
 246 (8.8%, 95% CI 5.5%-13.6%) over the entire study period, however, those with diabetes had the
 247 highest cumulative incidence in Period 2 (Table S3). In terms of other potential risk factors,
 248 those who reported recently drinking more than 6 alcoholic drinks on one occasion (9.9%, 95%
 249 CI 6.6%-14.3%) and those who used public transportation (8.6%, 95% CI 5.7%-12.6%) had
 250 higher cumulative incidence (Fig. 2, Table S3). Lower cumulative incidence was observed
 251 among those who, at enrollment, reported having asthma, immunosuppression, and depression.
 252




253
 254 **Figure 2** shows cumulative incidence estimates and 95% confidence intervals (CIs) for SARS-CoV-2 in CHASING COVID Cohort Study participants by
 255 risk factors. Estimates are adjusted for laboratory test kit error. All risk factors were measured at the baseline survey. Alcohol use is defined as having

256 more than 6 drinks on one occasion weekly, daily, or almost daily. (NPIs: Non-pharmaceutical interventions; HH: Household). The size of the square
 257 box/marker is proportional to the overall sample size in each group.

258

259 Incidence of recent SARS-CoV-2 seroconversion and potential risk factors

260 Figure 3 (and Table S4) shows more recent seroconversions and incidence rates among 3,280
 261 initially seronegative persons who had a subsequent serologic test during November 2020-
 262 January 2021 (Fig. S2), stratified by risk factors that were present prior to or between serologic
 263 tests. There were 145 observed seroconversions over 1,562 person years of follow-up among the
 264 3,280 participants, for an overall incidence rate of 9.3 per 100 person years (PY) (95% CI 7.9-
 265 11.0). The rate ratio (RR) for incident SARS-CoV-2 infection was higher for males than females
 266 (RR: 1.34, 95% CI 0.96-1.87), Hispanics (RR: 2.11, 95% CI 1.40-3.12) and non-Hispanic Blacks
 267 (RR 1.79, 95% CI 0.96-3.13) compared with non-Hispanic Whites. In contrast to cumulative
 268 incidence estimates, incidence rates reflecting more recent seroconversions were higher among
 269 those in rural versus urban areas (RR 1.52, 95% CI 1.04-2.22), those in the Midwest (RR 1.62,
 270 95% CI 0.98-2.69), the South (RR 1.73, 95% CI 1.1-2.75), and the West (RR 1.34, 95% CI 0.79-
 271 2.2) compared to the Northeast. Of note, essential workers had higher incidence than non-
 272 essential workers (RR 1.65, 95% CI 1.09--2.46).




273

274 **Figure 3** shows risk ratio estimates and 95% confidence intervals (CIs) for recent SARS-CoV-2 seroconversion (May 2020-January 2021) in CHASING
275 COVID Cohort Study participants by demographic factors. Essential workers include people working in law enforcement, emergency management,
276 delivery, transportation, and construction. High risk group is defined as participants who either reported a comorbidity, were over 60 years old, or were
277 a smoker. The size of the square box/marker is proportional to the overall sample size in each group.

278

279 Figure 4 (and Table S5) shows recent seroconversions and incidence rates for epidemiologic
280 risk factors. Living in more crowded households was associated with higher incidence than
281 living in less crowded households (RR 1.61, 95% CI 1.08-2.32). Compared with referent groups
282 in Figure 4, there was also higher incidence among those who dined indoors at restaurants/bars
283 (RR 1.95, 95% CI 1.38-2.83); those who visited a place of worship (RR 1.95, 95% CI 1.25-2.93);
284 those who wore a mask only sometimes while grocery shopping (RR 2.49, 95% CI 1.31-4.36);
285 those who visited indoors with people not in their own household while always wearing a mask
286 (RR=2.6; 95% CI 1.6-4.4), while sometimes wearing a mask (RR=3.5; 95% CI 2.7-5.7 or while
287 never wearing a mask (RR=5.3; 95% CI 3.1-8.9); those working indoors at a place of
288 employment while always wearing a mask (RR=2.0, 95% CI 1.4-2.8), while sometimes wearing
289 a mask (RR=2.0, 95% CI 1.1-3.5), or while never wearing a mask RR=3.7, 95% CI 1.3-8.5);
290 those attending a salon or gym with masks (RR=1.7, 95% CI 1.1-2.4); those who gathered
291 indoors and outdoors in groups of >10 (RR=1.9, 95% CI 1.2-2.0); and those that traveled by air
292 during the pandemic (RR 1.72, 95% CI 1.12-2.55).

293



294
 295 **Figure 4** shows risk ratio estimates and 95% confidence intervals (CIs) for recent SARS-CoV-2 seroconversion (May 2020-January 2021) in CHASING
 296 COVID Cohort Study participants by behavioral risk factors. For indoor mask use behavior, participants that did not engage in the respective behaviors
 297 were classified as N/A. The size of the square box/marker is proportional to the overall sample size in each group.

298
 299 **Clinical and public health outcomes among persons with serologic evidence of SARS-CoV-**
 300 **2 infection**

301 Among the 303 individuals who were positive for Total Ab during the study, only 121 (39.9%)
 302 were aware that they had a prior SARS-CoV-2 infection (Table S6). A substantial proportion of
 303 the 303 (27.4%) recalled no symptoms of COVID-like illness (i.e., were asymptomatic cases).
 304 Among the 145 more recent seroconverters in Period 2, the proportion reporting no symptoms
 305 was 25.5%, and another 60% reported milder symptoms that did not result in seeking care.

306 In terms of public health outcomes, 64.4% (195/303) said that they were tested for SARS-
 307 CoV-2 outside the study (Table S6), half of them (32% of total) reported having a positive
 308 SARS-CoV-2 test. However, only 30.7% of all 303 seropositives said that they had isolated
 309 themselves from people outside their household because of their infection, and, among those
 310 who did not live alone, even fewer (13.5% overall) said they isolated themselves from others
 311 within their household. In terms of contact tracing, 17.8% of all seropositives were asked about

312 contacts following diagnosis and only 12.2% of all seropositives had been informed by a contact
313 tracer that they may have had contact with someone confirmed to have SARS-CoV-2. Only 5.3%
314 of those diagnosed (3.3% of all seropositives) were told by a contact tracer to stay home for a
315 period of time because they had COVID-19.

316

317 **Repeat serologic testing outcomes**

318 A total of 303 persons who were ever seropositive by the Total Ab test contributed 392
319 seropositive Total Ab test results over the course of the study (Table S7). This included 134
320 persons with a positive Total Ab test in Period 1 and 258 in Period 2. Of the 258 Total Ab
321 positives in Period 2, 145 were recent seroconverters. There were 20 individuals who were Total
322 Ab positive in Period 1 but Total Ab negative in Period 2 (i.e., seroreverters and/or false
323 positives). Specifically, of 134 persons who tested Total Ab positive in Period 1 and had a
324 second test in Period 2, only 114 (85%) were still seropositive in Period 2. The median time
325 between specimen collection for these 20 individuals was 197 days (IQR 187-201 days). Of the
326 392 specimens that were positive on the Total Ab test from Period 1 or 2, 361 had sufficient
327 specimen quantity for further testing. Of these, 63.4% (201/361) were also positive on the spike
328 protein-based IgG test, including 65.7% (88/127) in Period 1, and 42.1% (113/234) in Period 2
329 (Table S7).

330

331 **DISCUSSION**

332 We report findings from one of the first community-based prospective epidemiologic studies
333 of SARS-CoV-2 incidence and risk factors, globally. We have prospectively characterized the
334 risk of incident SARS-CoV-2 infection in relation to a range of modifiable risk factors in the
335 U.S., using information on both past infection and recent seroconversion. With a well-
336 characterized sample of participants with evidence of prior infection, our study suggests that
337 public health strategies being widely used with the aim of reducing onward transmission
338 (quarantine, testing, isolation, and contact tracing) do not have high enough coverage during the
339 infectious period of SARS-CoV-2 to be effective at controlling community spread.

340 These are among the principal reasons why the U.S. has seen unmitigated increases in
341 community transmission, hospitalizations, and deaths from COVID-19. Unless and until herd
342 immunity can be achieved through a combination of natural infection and vaccine-induced

343 immunity, more nuanced understanding of the actual contribution of these factors over time is
344 needed. This in turn will facilitate more effective government and community public health
345 policies, actions and implementation strategies to control community spread, which is key to
346 preventing avoidable hospitalizations and deaths, and ultimately maximizing the impact of
347 vaccines. In areas where there is not an enforced lock down, our findings provide an evidence-
348 base for federal, state, and local policy focus on risk factors that appear to be potential drivers of
349 late-phase pandemic spread, such as indoor dining, mass gatherings, or not wearing masks when
350 outside the home.

351 Data on more recent seroconversions occurring between May 2020 and January 2021 in our
352 cohort suggest that elevated risk among essential workers, observed early in the U.S. pandemic,
353 has persisted. Essential workers risk exposure to SARS-CoV-2 not only in their workplace(s),
354 but also in their communities and as part of their commutes to and from work if they need to use
355 public transportation. The increased burden of risk of SARS-CoV-2 infection in essential
356 workers is then shared with their household members, among whom transmission is very
357 efficient.¹⁹ Along with this comes a higher burden of stress and anxiety among essential
358 workers.²⁰ The most immediate action that governments can take to help keep essential workers
359 safe is to minimize community transmission so that they are less likely to be exposed in the
360 workplace or as part of their commutes. Policies and other strategies should be considered and
361 implemented to ensure workplace safety (high quality masks, distancing, ventilation, paid sick
362 leave for those that cannot afford to miss work) and the safety of public transportation. Any
363 strategies should include prioritized access to SARS-CoV-2 vaccines for essential workers and,
364 until or in the absence of vaccination, rapid testing for essential workers and members of their
365 households. FDA-approved fully at-home rapid testing options are becoming more readily
366 available with or without a prescription, and past research has indicated an overall increase in the
367 uptake of testing with the addition of at-home testing options,^{21,22} making them a potentially
368 important strategy to increase early identification of new infections and subsequent interventions
369 to prevent onward transmission. In this later phase of the pandemic, healthcare workers in our
370 cohort had borderline elevated risk. Healthcare workers in the U.S. could be expected to have
371 lower risk of SARS-CoV-2 exposure in the workplace due to focused efforts to mitigate risk via
372 improved access to personal protective equipment and engineering controls. However, healthcare

373 workers also have ongoing community exposure, including possibly during their commutes to
374 and from work, that could put them at higher risk of SARS-CoV-2 exposure and acquisition.

375 Our study provides epidemiologic evidence of increased risk for a number of key exposures.
376 Living in more crowded households, defined as living in a multi-unit (i.e., apartment) building
377 with 4 or more household members, was associated with a 60% higher incidence of SARS-CoV-
378 2 infection compared with those living in less crowded households. Household transmission of
379 SARS-CoV-2 occurs with very high attack rates, and may also increase the risk of more severe
380 COVID-19 disease, requiring hospitalization.²³ Household crowding, more than population
381 density, was shown to be a characteristic of community transmission ‘hotspots’ in a recent
382 ecological analysis from the early phase of the pandemic.²⁴ When there are possible or confirmed
383 cases of SARS-CoV-2 among household members, when background community transmission is
384 substantial, or when the possibility of exposure outside the household is high (e.g., essential
385 workers), our study and others²⁵ suggest mask use in the household should be considered,
386 especially when it is otherwise not possible to limit potential exposure and spread in the
387 household by isolating or sequestering away from others. As the vaccine rollout continues, this is
388 particularly important to protect unvaccinated household members who may be at high risk for a
389 severe COVID-19 outcome.

390 We characterized the potential contribution of several other key risk factors, some of which
391 have been, or could be, the focus of state and federal policies, including dining indoors at a
392 restaurant/bar, visiting a place of worship, inconsistent mask use while grocery shopping or
393 visiting non-household members indoors (especially without masks), visiting a salon/gym,
394 gathering indoors in groups of 10 or more, and recent travel by airplane during the pandemic.
395 Working indoors, even while always masking but especially while never wearing a mask, was
396 strongly associated with higher infection rates. In addition to being potential individual policy
397 focus areas, we note that all of these risks can be mitigated by social distancing, workplace
398 safety, increased mask use, use of more effective masks (e.g., KN95), and use of more than one
399 mask.²⁶⁻²⁸

400 Finally, detailed examination of 303 individuals with serologic evidence of past SARS-CoV-
401 2 infection showed major gaps in the reach of public health interventions aimed at testing, self-
402 isolation, and contact tracing for people with SARS-CoV-2 (and their contacts). Indeed, many
403 with evidence of prior SARS-CoV-2 infection did not report a prior positive PCR test, and a

404 substantial proportion were asymptomatic, both greatly hindering the ability of public health
405 efforts to control spread. Furthermore, few people who had evidence of prior SARS-CoV-2
406 infection in our study reported having been reached by contact tracers. When considering the
407 large proportion of people with SARS-CoV-2 who have asymptomatic infection, undiagnosed
408 infection (with or without symptoms), the low likelihood of diagnosis during the pre-
409 symptomatic phase, the high number of new daily diagnoses and the often long delay between
410 testing and return of results, contact tracing (a strategy that requires rapid response and action
411 with high coverage early in the infectious period) is likely not a feasible strategy to control
412 community spread in the U.S.. Limited public health resources may be better spent instead on
413 messaging that emphasizes the importance of self-isolation after symptom onset or a positive
414 test. Verbal, written and electronic (SMS text, email) messaging should occur at the time of the
415 test, rather than after results are returned. In the event of a positive result, messaging at the time
416 of testing should also include instructions to notify close contacts, including in workplaces, that
417 they should quarantine and, if symptoms develop, self-isolate.

418 A shift in emphasis and resources away from contact tracing as a strategy to control
419 community spread would provide much needed resources at the state and local level to facilitate
420 more rapid and targeted delivery of vaccination, which has faltered in many areas to date. Many
421 in our cohort, as across the U.S., are not yet vaccinated, not yet eligible for or are not currently
422 willing to undergo vaccination²⁹, and will remain at risk for months to come. Accelerating
423 vaccine rollout, especially among those at high risk for a severe SARS-CoV-2 outcome and
424 essential workers, has the potential to save tens of thousands of lives.

425 All of the potential risk factors described in our study and the low uptake of public health
426 strategies conspire to create a perpetually disparate burden of risk among Hispanic and non-
427 Hispanic Black persons and essential workers, as well as their household members and their
428 communities. Our study suggests these inequalities have not been addressed to date in the U.S.,
429 and the ultimate drivers, which relate to structural racism and possibly other factors, need to be
430 unpacked by health departments and researchers.³⁰ There has been much research focused on
431 comorbid medical conditions and other biologic factors that may increase the risk of SARS-
432 CoV-2 acquisition or severity.³¹⁻³³ However, non-biological structural factors are the major
433 drivers of COVID-19 infection and severe outcomes, and the inequities by race/ethnicity,
434 occupation, geography, and income. These non-biological structural factors, such as household

435 crowding, the need to go to work to avoid income loss, and inequitable access to SARS-CoV-2
436 testing³⁴, create a disparate burden of SARS-CoV-2 exposure and incidence.³⁵ To date, no
437 targeted strategies or policies have been deployed that aim to protect those who cannot afford
438 missing work, including, but not only, essential workers. These disparities in SARS-CoV-2
439 exposure, incidence, hospitalization and death will likely be perpetuated and likely exacerbated
440 by differential uptake of the COVID-19 vaccines, driven by potentially flawed implementation
441 strategies that prevent equitable access to vaccination. It is incumbent upon public health leaders,
442 decision makers, and policy makers to anticipate and proactively design pandemic response
443 implementation strategies, including metrics, that account for and counteract the fundamental
444 and prevailing structural forces that without fail will otherwise create, perpetuate, or exacerbate
445 inequities in safety, health and well-being.³⁶⁻³⁹

446 Strengths of our cohort study include its prospective design, allowing direct observation of
447 seroconversions and incident COVID-19 infection among those who had no serologic evidence
448 of prior SARS-CoV-2 infection, with and without risk factors. Our cohort is also geographically
449 and sociodemographically diverse, facilitating assessment of geographic differences and
450 racial/ethnic disparities. We also measured and were able to estimate incidence rates associated
451 with a range of relevant epidemiologic risk factors.

452 Our study also has limitations worth noting. Most research studies deployed in the middle of
453 a pandemic, including ours, may produce biased estimates since they may not include complete
454 information on participants who died from COVID-19, or were too sick or otherwise too busy to
455 participate in the research activities, or enrolled but became lost to follow-up. Moreover, it is
456 possible that those who thought they had SARS-CoV-2 or were tested outside the study may
457 have been more or less likely to participate in follow-up serologic testing, which would lead our
458 seroincidence estimates to be biased in either direction. However, there was no systematic
459 difference between those who tested in Period 1 and Period 2 (Table S1). Separately, while we
460 have corrected our cumulative incidence estimates for laboratory test error¹⁸, the *observed*
461 cumulative incidence in our cohort may be lower than the *true* cumulative incidence in our
462 cohort because of waning of SARS-CoV-2 antibodies. Recent studies suggest waning of
463 antibodies to both nucleocapsid and spike proteins², which combined with the timing of
464 specimen collection relative to infection for many participants in our cohort (median of 190
465 days)⁹, could mean that we have underestimated the true cumulative incidence. Next, as with any

466 observational cohort study, estimated associations between SARS-CoV-2 risk factors and
467 incidence are subject to confounding. The crude associations we presented could be over- or
468 underestimated, and also may vary by setting. For example, the effect of indoor dining may be
469 different in areas of lower versus higher levels of community transmission. Our study also had
470 limited statistical power due to our sample size and the relatively short duration of follow-up.
471 Finally, while our study is well-suited to characterize the risks related to SARS-CoV-2
472 acquisition, it is less well-suited to examine factors related to onward transmission from
473 participants who had SARS-CoV-2 infection. However, in lieu of this, we have endeavored to
474 describe the coverage of public health-related outreach to persons in our cohort who had
475 evidence of past SARS-CoV-2 infection and identified some areas in need of improvement, such
476 as the need for improvements in the uptake of testing and self-isolation.

477

478 **Conclusion**

479 Modifiable risk factors and poor reach of public health strategies continue to drive transmission
480 of SARS-CoV-2 across the U.S.. It is critical to address inequities in incidence, reduce risk
481 factors, and improve the reach of public health strategies of testing and self-isolation in the
482 vaccine era. Given the properties of the SARS-CoV-2 virus, including the substantial
483 asymptomatic and pre-symptomatic phases during the SARS-CoV-2 infectious period, the
484 magnitude of cases and the need to act quickly, contact tracing is not a viable public health
485 strategy to control the spread of the pandemic in the U.S.. Our cumulative incidence estimates
486 suggest that many in our cohort remain at risk for SARS-CoV-2, including those with risk factors
487 for infection and severe disease. While SARS-CoV-2 vaccines will likely reduce the risk of
488 COVID-19 disease and possibly SARS-CoV-2 acquisition substantially for this group, this will
489 likely take some time due to both the pace of the vaccine rollout and vaccine hesitancy. The
490 CHASING COVID Cohort Study will continue to monitor SARS-CoV-2 outcomes, including
491 vaccine uptake, through December 2021.

492

493

494 **CONTRIBUTORS**

495 DN, MR, SGK, MMR, conceptualized the study. MR, MC and DN performed statistical
496 analyses. DN and MR wrote the first draft of the paper. DN, MR, MC, SGK, and AP contributed

497 to interpreting the data, DN, RZ, MR, MC, SGK, WY, AB, CM, SK, AM, MMR, DW, AP, LW,
498 CG and to the writing and revising of the manuscript, SGK, WY, AB, CM, SK, and DN
499 contributed to data collection, cleaning and management. DN, SGK, MMR and CG contributed
500 to obtaining funding for the research.

501

502 **ACKNOWLEDGEMENTS**

503 The authors wish to thank the participants of the CHASING COVID Cohort Study. We are
504 grateful to you for your contributions to the advancement of science around the SARS-CoV-2
505 pandemic. We thank Prof. Patrick Sullivan and MTL for local validation work on the serologic
506 assays for use with DBS that greatly benefited our study. We are also grateful to MTL Labs for
507 processing specimen collection kits and serologic testing of our cohort's specimens.

508

509 **FUNDING**

510 Funding for this project is provided by The National Institute of Allergy and Infectious Diseases
511 (NIAID), award number 3UH3AI133675-04S1 (MPIs: D Nash and C Grov), the
512 CUNY Institute for Implementation Science in Population Health (cunyisph.org) and the
513 COVID-19 Grant Program of the CUNY Graduate School of Public Health and Health Policy,
514 and National Institute of Child Health and Human Development grant P2C HD050924 (Carolina
515 Population Center).

516 **REFERENCES**

- 517 1. CDC, COVID Data Tracker (2020), (available at <https://covid.cdc.gov/covid-data-tracker/>).
- 518 2. K. L. Bajema, R. E. Wiegand, K. Cuffe, S. V. Patel, R. Iachan, T. Lim, A. Lee, D. Moyse, F.
519 P. Havers, L. Harding, A. M. Fry, A. J. Hall, K. Martin, M. Biel, Y. Deng, W. A. Meyer 3rd,
520 M. Mathur, T. Kyle, A. V. Gundlapalli, N. J. Thornburg, L. R. Petersen, C. Edens,
521 Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020. *JAMA Intern.*
522 *Med.* (2020), doi:10.1001/jamainternmed.2020.7976.
- 523 3. F. J. Angulo, L. Finelli, D. L. Swerdlow, Estimation of US SARS-CoV-2 Infections,
524 Symptomatic Infections, Hospitalizations, and Deaths Using Seroprevalence Surveys. *JAMA*
525 *Netw Open.* **4**, e2033706 (2021).
- 526 4. H. Kalish, C. Klumpp-Thomas, S. Hunsberger, H. A. Baus, M. P. Fay, N. Siripong, J. Wang,
527 J. Hicks, J. Mehalko, J. Travers, M. Drew, K. Pauly, J. Spathies, T. Ngo, K. M. Adusei, M.
528 Karkanitsa, J. A. Croker, Y. Li, B. I. Graubard, L. Czajkowski, O. Belliveau, C. Chairez, K.
529 Snead, P. Frank, A. Shunmugavel, A. Han, L. T. Giurgea, L. A. Rosas, R. Bean, R. Athota,
530 A. Cervantes-Medina, M. Gouzoulis, B. Heffelfinger, S. Valenti, R. Caldararo, M. M.
531 Kolberg, A. Kelly, R. Simon, S. Shafiq, V. Wall, S. Reed, E. W. Ford, R. Lokwani, J.-P.
532 Denson, S. Messing, S. G. Michael, W. Gillette, R. P. Kimberly, S. E. Reis, M. D. Hall, D.
533 Esposito, M. J. Memoli, K. Sadtler, Mapping a Pandemic: SARS-CoV-2 Seropositivity in
534 the United States. *medRxiv* (2021), doi:10.1101/2021.01.27.21250570.
- 535 5. D. Buitrago-Garcia, D. Egli-Gany, M. J. Counotte, S. Hossmann, H. Imeri, A. M. Ipekci, G.
536 Salanti, N. Low, Occurrence and transmission potential of asymptomatic and
537 presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis.
538 *PLoS Med.* **17**, e1003346 (2020).
- 539 6. H. J. Hutchins, B. Wolff, R. Leeb, J. Y. Ko, E. Odom, J. Willey, A. Friedman, R. H. Bitsko,
540 COVID-19 Mitigation Behaviors by Age Group - United States, April-June 2020. *MMWR*
541 *Morb. Mortal. Wkly. Rep.* **69**, 1584–1590 (2020).
- 542 7. M. Lipsitch, D. L. Swerdlow, L. Finelli, Defining the epidemiology of Covid-19—studies

- 543 needed. *N. Engl. J. Med.* **382**, 1194–1196 (2020).
- 544 8. D. P. Oran, E. J. Topol, The Proportion of SARS-CoV-2 Infections That Are Asymptomatic
545 : A Systematic Review. *Ann. Intern. Med.* (2021), doi:10.7326/M20-6976.
- 546 9. M. Robertson, S. Kulkarni, A. Berry, C. Mirzayi, A. R. Maroko, R. Zimba, D.
547 Westmoreland, C. Grov, A. Parcesepe, L. Waldron, D. Nash, A national prospective cohort
548 study of SARS/COV2 pandemic outcomes in the U.S.: The CHASING COVID Cohort.
549 *medRxiv* (2020), doi:10.1101/2020.04.28.20080630.
- 550 10. C. Grov, D. A. Westmoreland, P. B. Carneiro, M. Stief, C. MacCrate, C. Mirzayi, D. W.
551 Pantalone, V. V. Patel, D. Nash, Recruiting vulnerable populations to participate in HIV
552 prevention research: findings from the Together 5000 cohort study. *Annals of Epidemiology.*
553 **35** (2019), pp. 4–11.
- 554 11. D. Nash, M. Stief, C. MacCrate, C. Mirzayi, V. V. Patel, D. Hoover, D. W. Pantalone, S.
555 Golub, G. Millett, A. B. D’Angelo, D. A. Westmoreland, C. Grov, A Web-Based Study of
556 HIV Prevention in the Era of Pre-Exposure Prophylaxis Among Vulnerable HIV-Negative
557 Gay and Bisexual Men, Transmen, and Transwomen Who Have Sex With Men: Protocol for
558 an Observational Cohort Study. *JMIR Research Protocols.* **8** (2019), p. e13715.
- 559 12. C. Grov, D. Westmoreland, H. J. Rendina, D. Nash, Seeing Is Believing? Unique
560 Capabilities of Internet-Only Studies as a Tool for Implementation Research on HIV
561 Prevention for Men Who Have Sex With Men: A Review of Studies and Methodological
562 Considerations. *J. Acquir. Immune Defic. Syndr.* **82 Suppl 3**, S253–S260 (2019).
- 563 13. CDC - BRFSS (2020), (available at <https://www.cdc.gov/brfss/index.html>).
- 564 14. T. A. Santibanez, J. A. Singleton, S. S. Santibanez, P. Wortley, B. P. Bell, Socio-
565 demographic differences in opinions about 2009 pandemic influenza A (H1N1) and seasonal
566 influenza vaccination and disease among adults during the 2009--2010 influenza season.
567 *Influenza Other Respi. Viruses.* **7**, 383–392 (2013).
- 568 15. S. Kumar, S. C. Quinn, K. H. Kim, L. H. Daniel, V. S. Freimuth, The impact of workplace
569 policies and other social factors on self-reported influenza-like illness incidence during the

- 570 2009 H1N1 pandemic. *Am. J. Public Health*. **102**, 134–140 (2012).
- 571 16. M. T. Niles, R. Neff, E. Biehl, F. Bertmann, E. H. Morgan, T. Wentworth, Food Access and
572 Security During Coronavirus Survey- Version 1.0 (2020), , doi:10.7910/DVN/RQ6NMG.
- 573 17. Center for Devices, Radiological Health, EUA Authorized Serology Test Performance
574 (2021), (available at [https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-](https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance)
575 [performance](https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance)).
576
- 577 18. C. T. Sempos, L. Tian, Adjusting Coronavirus Prevalence Estimates for Laboratory Test Kit
578 Error. *Am. J. Epidemiol.* **190**, 109–115 (2021).
- 579 19. Z. J. Madewell, Y. Yang, I. M. Longini Jr, M. E. Halloran, N. E. Dean, Household
580 Transmission of SARS-CoV-2: A Systematic Review and Meta-analysis. *JAMA Netw Open*.
581 **3**, e2031756 (2020).
- 582 20. A. M. Parcesepe, M. Robertson, A. Berry, A. Maroko, R. Zimba, C. Grov, D.
583 Westmoreland, S. Kulkarni, M. Rane, W. Salgado-You, C. Mirzayi, L. Waldron, D. Nash,
584 The relationship between anxiety, health, and potential stressors among adults in the United
585 States during the COVID-19 pandemic. *medRxiv* (2020), doi:10.1101/2020.10.30.20221440.
- 586 21. R. Zimba, S. Kulkarni, A. Berry, W. You, C. Mirzayi, D. Westmoreland, A. Parcesepe, L.
587 Waldron, M. Rane, S. Kochhar, M. Robertson, A. Maroko, C. Grov, D. Nash, SARS-CoV-2
588 Testing Service Preferences of Adults in the United States: Discrete Choice Experiment.
589 *JMIR Public Health Surveill.* **6**, e25546 (2020).
- 590 22. M. L. Romo, R. Zimba, S. Kulkarni, A. Berry, W. You, C. Mirzayi, D. Westmoreland, A.
591 M. Parcesepe, L. Waldron, M. Rane, S. Kochhar, M. Robertson, A. R. Maroko, C. Grov, D.
592 Nash, Patterns of SARS-CoV-2 testing preferences in a national cohort in the United States.
593 *medRxiv* (2020), doi:10.1101/2020.12.22.20248747.
- 594 23. D. Nash, S. Qasmieh, M. Robertson, M. Rane, R. Zimba, S. Kulkarni, A. Berry, W. You, C.
595 Mirzayi, D. Westmoreland, A. Parcesepe, L. Waldron, S. Kochhar, A. R. Maroko, C. Grov,
596 Household factors and the risk of severe COVID-like illness early in the US pandemic.

- 597 *medRxiv* (2020), doi:10.1101/2020.12.03.20243683.
- 598 24. A. Maroko, D. Nash, B. Pavlonis, Covid-19 and Inequity: A comparative spatial analysis of
599 New York City and Chicago hot spots. *J. Urban Health* (2020).
- 600 25. Y. Wang, H. Tian, L. Zhang, M. Zhang, D. Guo, W. Wu, X. Zhang, G. L. Kan, L. Jia, D.
601 Huo, B. Liu, X. Wang, Y. Sun, Q. Wang, P. Yang, C. R. MacIntyre, Reduction of secondary
602 transmission of SARS-CoV-2 in households by face mask use, disinfection and social
603 distancing: a cohort study in Beijing, China. *BMJ Glob Health*. **5** (2020),
604 doi:10.1136/bmjgh-2020-002794.
- 605 26. CDC, Scientific brief: Community use of cloth masks to control the spread of SARS-CoV-2
606 (2020), (available at <https://www.cdc.gov/coronavirus/2019-ncov/more/masking-science-sars-cov2.html>).
- 608 27. Y. Li, M. Liang, L. Gao, M. Ayaz Ahmed, J. P. Uy, C. Cheng, Q. Zhou, C. Sun, Face masks
609 to prevent transmission of COVID-19: A systematic review and meta-analysis. *Am. J. Infect.*
610 *Control* (2020), doi:10.1016/j.ajic.2020.12.007.
- 611 28. D. K. Chu, E. A. Akl, S. Duda, K. Solo, S. Yaacoub, H. J. Schünemann, COVID-19
612 Systematic Urgent Review Group Effort (SURGE) study authors, Physical distancing, face
613 masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and
614 COVID-19: a systematic review and meta-analysis. *Lancet*. **395**, 1973–1987 (2020).
- 615 29. K. A. Fisher, S. J. Bloomstone, J. Walder, S. Crawford, H. Fouayzi, K. M. Mazor, Attitudes
616 Toward a Potential SARS-CoV-2 Vaccine : A Survey of U.S. Adults. *Ann. Intern. Med.* **173**,
617 964–973 (2020).
- 618 30. L. N. Borrell, J. R. Elhawary, E. Fuentes-Afflick, J. Witonsky, N. Bhakta, A. H. B. Wu, K.
619 Bibbins-Domingo, J. R. Rodríguez-Santana, M. A. Lenoir, J. R. Gavin 3rd, R. A. Kittles, N.
620 A. Zaitlen, D. S. Wilkes, N. R. Powe, E. Ziv, E. G. Burchard, Race and Genetic Ancestry in
621 Medicine - A Time for Reckoning with Racism. *N. Engl. J. Med.* **384**, 474–480 (2021).
- 622 31. A. Emami, F. Javanmardi, N. Pirbonyeh, A. Akbari, Prevalence of underlying diseases in
623 hospitalized patients with COVID-19: a systematic review and meta-analysis. *Archives of*

- 624 *academic emergency medicine*. **8** (2020) (available at
625 <https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7096724/>).
- 626 32. S. Richardson, J. S. Hirsch, M. Narasimhan, J. M. Crawford, T. McGinn, K. W. Davidson,
627 the Northwell COVID-19 Research Consortium, D. P. Barnaby, L. B. Becker, J. D. Chelico,
628 S. L. Cohen, J. Cookingham, K. Coppa, M. A. Diefenbach, A. J. Dominello, J. Duer-Hefelee,
629 L. Falzon, J. Gitlin, N. Hajjzadeh, T. G. Harvin, D. A. Hirschwerk, E. J. Kim, Z. M. Kozel,
630 L. M. Marrast, J. N. Mogavero, G. A. Osorio, M. Qiu, T. P. Zanos, Presenting
631 Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With
632 COVID-19 in the New York City Area. *JAMA*. **323**, 2052–2059 (2020).
- 633 33. C. M. Petrilli, S. A. Jones, J. Yang, H. Rajagopalan, L. O’Donnell, Y. Chernyak, K. A.
634 Tobin, R. J. Cerfolio, F. Francois, L. I. Horwitz, Factors associated with hospital admission
635 and critical illness among 5279 people with coronavirus disease 2019 in New York City:
636 prospective cohort study. *BMJ*. **369**, m1966 (2020).
- 637 34. A. Mody, K. Pfeifauf, E. H. Geng, Using Lorenz Curves to Measure Racial Inequities in
638 COVID-19 Testing. *JAMA Netw Open*. **4**, e2032696 (2021).
- 639 35. G. Ogedegbe, J. Ravenell, S. Adhikari, M. Butler, T. Cook, F. Francois, E. Iturrate, G. Jean-
640 Louis, S. A. Jones, D. Onakomaiya, C. M. Petrilli, C. Pulgarin, S. Regan, H. Reynolds, A.
641 Seixas, F. M. Volpicelli, L. I. Horwitz, Assessment of Racial/Ethnic Disparities in
642 Hospitalization and Mortality in Patients With COVID-19 in New York City. *JAMA Netw*
643 *Open*. **3**, e2026881 (2020).
- 644 36. D. Nash, E. Geng, Goal-Aligned, Epidemic Intelligence for the Public Health Response to
645 the COVID-19 Pandemic. *Am. J. Public Health*. **110**, 1154–1156 (2020).
- 646 37. D. Nash, Designing and Disseminating Metrics to Support Jurisdictional Efforts to End the
647 Public Health Threat Posed by HIV Epidemics. *Am. J. Public Health*. **110**, 53–57 (2020).
- 648 38. Z. D. Bailey, J. M. Feldman, M. T. Bassett, How Structural Racism Works - Racist Policies
649 as a Root Cause of U.S. Racial Health Inequities. *N. Engl. J. Med.* (2020),
650 doi:10.1056/NEJMms2025396.

- 651 39. Z. D. Bailey, N. Krieger, M. Agénor, J. Graves, N. Linos, M. T. Bassett, Structural racism
652 and health inequities in the USA: evidence and interventions. *Lancet*. **389**, 1453–1463
653 (2017).

SUPPLEMENTAL MATERIALS




Fig. S1.
Geographic distribution of CHASING COVID Cohort participants, N=6,745




Fig. S2.

Timing of first (red) and second (blue) dried blood spot specimen collection in the CHASING COVID Cohort Study, including follow-up interview milestones

Table S1. Baseline characteristics and serologic testing of CHASING COVID Cohort Study participants by time period of testing

	All participants		Participants with one or more serologic test		Participants with a serologic test in Period 1 (May-September 2020)		Participants with a serologic test in Period 2 (November 2020-January 2021)*	
	N	%	N	%	N	%	N	%
Total	6,745	100%	4459	66%	4235	63%	3615	54%
Age*								
Median (IQR)	37 (29,51)		41 (31, 55)		41, (32, 56)		41, (32, 56)	
18-29	1804	26.75	861	19.3	801	18.9	656	18.4
30-39	1965	29.13	1246	27.9	1177	27.8	1004	27.8
40-49	1160	17.2	846	19.0	809	19.1	686	19.0
50-59	792	11.74	646	14.5	620	14.6	541	15.0
60+	1024	15.18	860	19.3	828	19.6	719	19.9
Gender								
Male	3047	45.17	1991	44.7	1900	44.9	1607	44.5
Female	3527	52.29	2337	52.4	2212	52.2	1906	52.7
Non-Binary/Transgender	171	2.54	131	2.9	123	2.9	102	2.8
Race/Ethnicity*								
Non-Hispanic White	3859	56.8	2953	66.3	2833	66.9	2410	66.7
Hispanic	1310	19.42	669	15.0	623	14.7	550	15.2
Non-Hispanic Black	851	12.62	369	8.3	342	8.1	285	7.9
Asian	439	6.51	283	6.3	262	6.2	228	6.3
Pacific Islander	36	0.53	18	0.4	18	0.4	15	0.4
Other	250	3.71	167	3.8	157	3.7	127	3.5
Education								
Less than high school	123	1.82	52	1.2	47	1.1	43	1.2
High school graduate	879	13.03	399	9.0	367	8.7	308	8.5
Some college	1889	28.01	1126	25.3	1053	24.9	871	24.1

College graduate	3854	57.14	2882	64.6	2768	65.4	2393	66.2
Employment*								
Employed	4249	62.99	2741	61.5	2613	61.7	2216	61.3
Out of work	830	12.31	535	12.0	503	11.9	429	11.9
Homemaker	352	5.22	240	5.4	225	5.3	194	5.4
Student	610	9.04	362	8.1	330	7.8	283	7.8
Retired	704	10.44	581	13.0	564	13.3	493	13.6
Household income*								
Less than \$35,000	2180	32.32	1288	28.9	1213	28.6	1009	27.9
\$35-49,999	753	11.16	487	10.9	457	10.8	402	11.1
\$50-69,999	960	14.23	635	14.2	600	14.2	532	14.7
\$70-99,999	1058	15.69	734	16.5	706	16.7	624	17.3
\$100,000+	1794	26.6	1315	29.5	1259	29.7	1048	29.0
Setting*								
Urban	2974	44.09	1962	44.0	1873	44.2	1572	43.5
Suburban	1760	26.09	1143	25.6	1092	25.8	928	25.7
Rural	2011	29.81	1354	30.4	1270	30.0	1115	30.8
Geographic region*								
Northeast	1882	27.9	1294	29.0	1244	29.4	1023	28.3
Midwest	1127	16.71	794	17.8	760	18.0	655	18.1
South	2103	31.18	1269	28.5	1188	28.1	1037	28.7
West	1625	24.09	1097	24.6	1038	24.5	896	24.8
US Dependent Territories	8	0.12	5	0.1	5	0.1	4	0.1
Healthcare worker*								
No	5948	88.18	4042	90.7	3835	90.6	3283	90.8
Yes	797	11.82	417	9.4	400	9.5	332	9.2
Essential worker								
No	5601	83	3858	86.5	3662	86.5	3137	86.8
Yes	1144	17	601	13.5	573	13.5	478	13.2
Higher risk for severe COVID**								
No	3167	46.95	2074	46.5	1974	46.6	1669	46.2
Yes	3578	53.05	2385	53.5	2261	53.4	1946	53.8

*<5% of the data were missing for this variable and values for those with missing values were imputed by assigning the most common

value for this variable

** >60 years old, or reported co-morbidity, or current smoker.

Table S1.

Baseline characteristics and serologic testing of CHASING COVID Cohort Study participants by time period of testing

Table S2. Crude and adjusted** cumulative incidence estimates of SARS-CoV-2 infection in CHASING COVID Cohort Study participants by time period of testing

	All unique participants with a serologic test result (Period 1 or Period 2) N=4,459				Participants with a serologic test in Period 1 (N=4,235)				Participants with a serologic test in Period 2 (N=3,615)			
	Number positive	Total	Crude cumulative incidence (95% CI)	Adjusted cumulative incidence (95% CI)	Number positive	Total	Crude cumulative incidence (95% CI)	Adjusted cumulative incidence (95% CI)	Number positive	Total	Crude cumulative incidence (95% CI)	Adjusted cumulative incidence (95% CI)
Total	303	4459	6.8 (6.1, 7.6)	6.3 (5.5, 7.1)	134	4235	3.2 (2.6, 3.7)	2.6 (2, 3.1)	258	3615	7.2 (6.3, 8)	6.7 (5.8, 7.5)
Age group*												
18-29	66	861	7.7 (5.9, 9.4)	7.2 (5.3, 8.9)	28	801	3.5 (2.2, 4.8)	2.4 (1.1, 3.7)	57	665	8.6 (6.4, 10.7)	7.6 (5.4, 9.7)
30-39	94	1246	7.5 (6.1, 9.0)	7 (5.5, 8.5)	46	1177	3.9 (2.8, 5.0)	2.8 (1.7, 4)	76	1004	7.6 (5.9, 9.2)	6.6 (4.9, 8.2)
40-49	60	846	7.1 (5.4, 8.8)	6.6 (4.8, 8.3)	27	809	3.3 (2.1, 4.6)	2.2 (1, 3.5)	47	686	6.9 (5, 8.7)	5.9 (3.9, 7.7)
50-59	45	646	7.1 (5.1, 9.1)	6.6 (4.5, 8.6)	20	620	3.4 (2, 4.8)	2.3 (0.9, 3.7)	44	541	8.3 (6, 10.6)	7.3 (5, 9.6)
60+	38	860	4.4 (3.1, 5.8)	3.8 (2.5, 5.2)	13	828	1.6 (0.7, 2.4)	0.5 (0, 1.3)	34	719	4.7 (3.2, 6.3)	3.6 (2.1, 5.3)
Gender												
Male	165	1991	8.3 (7.1, 9.5)	7.8 (6.6, 9)	79	1900	4.2 (3.3, 5.1)	3.1 (2.2, 4)	134	1607	8.3 (7, 9.7)	7.3 (6, 8.7)
Female	134	2337	5.8 (4.8, 6.7)	5.2 (4.2, 6.2)	54	2212	2.5 (1.8, 3.1)	1.4 (0.7, 2)	120	1906	6.4 (5.3, 7.4)	5.4 (4.2, 6.4)
Non-Binary/Transgender	4	131	3.1 (1.1, 6.1)	2.5 (0.4, 5.5)	1	123	0.8 (0, 2.4)	0 (0, 1.3)	4	102	3.9 (1.5, 7.7)	2.8 (0, 6.7)
Race/Ethnicity*												
Non-Hispanic White	174	2953	5.9 (5.1, 6.8)	5.3 (4.5, 6.3)	81	2833	2.9 (2.3, 3.5)	1.8 (1.2, 2.4)	156	2410	6.5 (5.5, 7.5)	5.5 (4.4, 6.5)
Hispanic	71	669	10.6 (8.3, 13.0)	10.2 (7.8, 12.6)	26	623	4.2 (2.6, 5.8)	3.1 (1.5, 4.8)	57	550	10.4 (7.8, 12.9)	9.4 (6.8, 11.9)
Non-Hispanic Black	31	369	8.4 (5.6, 11.2)	7.9 (5, 10.8)	13	342	3.8 (1.8, 5.8)	2.7 (0.7, 4.8)	25	285	8.8 (5.5, 12.1)	7.8 (4.4, 11.1)
Asian	16	283	5.7 (3.0, 8.3)	5.1 (2.4, 7.8)	9	262	3.4 (1.2, 5.6)	2.3 (0.1, 4.6)	12	228	5.3 (2.4, 8.2)	4.2 (1.3, 7.2)
Pacific Islander	0	18	0 (0, 0)		0	18	0 (0, 17.6)	0 (0, 16.7)	0	15		
Other	11	167	6.6 (3.7, 11.4)	6.1 (3.1, 11)	5	157	3.2 (0.4, 5.9)	2.1 (0, 4.9)	8	127	6.3 (2.1, 10.5)	5.3 (1, 9.5)
Education												
Less than high school	5	52	9.6 (1.6, 21.0)	9.1 (0.9, 20.9)	3	47	6.4 (0, 13.4)	5.4 (0, 12.4)	3	43	7 (0, 14.6)	6 (0, 13.7)
High school graduate	34	399	8.5 (5.8, 11.3)	8 (5.2, 10.9)	13	367	3.5 (1.7, 5.4)	2.4 (0.6, 4.3)	29	308	9.4 (6.2, 12.7)	8.4 (5.2, 11.7)
Some college	72	1126	6.4 (5.0, 7.8)	5.9 (4.4, 7.3)	29	1053	2.8 (1.8, 3.8)	1.7 (0.7, 2.7)	62	871	7.1 (5.4, 8.8)	6.1 (4.3, 7.8)
College graduate	192	2882	6.7 (5.8, 7.6)	6.2 (5.2, 7.1)	89	2768	3.3 (2.6, 3.9)	2.2 (1.5, 2.8)	164	2393	6.9 (5.8, 7.9)	5.9 (4.8, 6.9)
Employment*												
Employed	208	2741	7.6 (6.6, 8.6)	7.1 (6.1, 8.1)	95	2613	2.4 (1.5, 3.4)	1.3 (0.4, 2.3)	179	2216	8.1 (6.9, 9.2)	7.1 (5.9, 8.2)
Out of work	34	535	6.4 (4.3, 8.4)	5.9 (3.7, 7.9)	15	503	1.9 (0.1, 3.7)	0.8 (0, 2.6)	26	429	6.1 (3.8, 8.3)	5.1 (2.7, 7.3)

Homemaker	14	240	6.2 (3.2, 9.3)	5.7 (2.6, 8.8)	6	225	3.5 (0.5, 6.4)	2.4 (0, 5.4)	11	194	6.2 (3, 9.5)	5.2 (1.9, 8.5)
Student	24	362	6.7 (4.1, 9.2)	6.2 (3.5, 8.7)	10	330	2 (0, 4.7)	0.9 (0, 3.6)	21	283	7.4 (4.4, 10.5)	6.4 (3.3, 9.5)
Retired	23	581	4.0 (2.4, 5.5)	3.4 (1.7, 4.9)	8	564	1.2 (0, 2.6)	0.1 (0, 1.5)	21	493	4.3 (2.5, 6)	3.2 (1.4, 5)
Household income*												
Less than \$35,000	82	1288	6.4 (5.1, 7.8)	5.9 (4.5, 7.3)	31	1213	2.3 (1.4, 3.1)	1.2 (0.3, 2)	71	1009	7.1 (5.5, 8.7)	6.1 (4.4, 7.7)
\$35-49,999	40	487	8.2 (5.8, 10.6)	7.7 (5.2, 10.2)	17	457	3.7 (2, 5.4)	2.6 (0.9, 4.3)	34	402	8.5 (5.7, 11.2)	7.5 (4.7, 10.2)
\$50-69,999	39	635	6.1 (4.3, 8.0)	5.5 (3.7, 7.5)	16	600	2.7 (1.4, 4)	1.6 (0.3, 2.9)	31	532	5.8 (3.8, 7.8)	4.8 (2.7, 6.8)
\$70-99,999	57	734	7.8 (5.8, 9.7)	7.3 (5.2, 9.2)	26	706	3.7 (2.3, 5.1)	2.6 (1.2, 4)	49	624	7.9 (5.7, 9.9)	6.9 (4.7, 8.9)
\$100,000+	85	1315	6.5 (5.1, 7.8)	6 (4.5, 7.3)	44	1259	3.5 (2.5, 4.5)	2.4 (1.4, 3.4)	73	1048	6 (5.4, 8.5)	5 (4.3, 7.5)
Setting*												
Urban	136	1962	6.9 (5.8, 8.1)	6.4 (5.2, 7.6)	71	1873	3.9 (3, 4.8)	2.8 (1.9, 3.7)	111	1572	7.1 (5.8, 8.3)	6.1 (4.8, 7.3)
Suburban	78	1143	6.8 (5.4, 8.3)	5.8 (4.3, 7.3)	35	1092	3.2 (2.2, 4.3)	2.1 (1.1, 3.2)	68	928	7.3 (5.7, 9)	6.3 (4.7, 8)
Rural	89	1354	6.7 (5.3, 8.0)	5.7 (4.2, 7)	28	1270	2.3 (1.5, 3.1)	1.2 (0.4, 2)	79	1115	7.2 (5.7, 8.7)	6.2 (4.7, 7.7)
Geographic region*												
Northeast	106	1294	8.3 (6.8, 9.8)	7.8 (6.3, 9.4)	72	1244	5.9 (4.6, 7.2)	4.9 (3.5, 6.2)	85	1023	8.4 (6.7, 10.1)	7.4 (5.7, 9.1)
Midwest	50	794	6.3 (4.6, 8.0)	5.8 (4, 7.5)	16	760	2.1 (1.1, 3.1)	1 (0, 2)	49	655	7.5 (5.5, 9.5)	6.5 (4.4, 8.5)
South	90	1269	7.2 (5.7, 8.6)	6.6 (5.2, 8.1)	31	1188	2.6 (1.8, 3.6)	1.5 (0.7, 2.5)	72	1037	6.9 (5.5, 8.6)	5.9 (4.4, 7.6)
West	57	1097	5.2 (3.9, 6.5)	4.6 (3.3, 6)	15	1038	1.5 (0.7, 2.2)	0.4 (0, 1.1)	52	896	5.8 (4.3, 7.3)	4.8 (3.2, 6.3)
US Dep	0	5	0 (0, 0)		0	5	0 (0, 0)	0 (0, 0)	0	4	0 (0, 0)	0 (0, 0)
Healthcare worker*												
No	274	4042	6.8 (6.0, 7.6)	6.3 (5.4, 7.1)	124	3835	3 (2.2, 3.7)	1.9 (1.1, 2.6)	233	3283	7.1 (6.3, 8)	6.1 (5.3, 7)
Yes	29	417	7.0 (4.5, 9.4)	6.5 (3.9, 8.9)	10	400	2.4 (0.1, 4.7)	1.3 (0, 3.6)	25	332	7.5 (4.7, 10.4)	6.5 (3.6, 9.4)
Essential worker												
No	257	3858	6.7 (5.9, 7.5)	6.2 (5.3, 7)	120	3662	3.3 (2.7, 3.9)	1.9 (1.3, 2.5)	218	3137	7 (6.1, 7.9)	6 (5.1, 6.9)
Yes	46	601	7.7 (5.5, 9.8)	7.2 (4.9, 9.4)	14	573	2.4 (1.2, 3.7)	3.3 (1.8, 4.9)	40	478	8.4 (5.9, 10.9)	7.4 (4.9, 9.9)
High Risk group***												
No	162	2074	7.8 (6.7, 9.0)	7.3 (6.2, 8.5)	79	1974	4.0 (3.1, 4.9)	3 (2.1, 3.9)	136	1669	8.2 (6.8, 9.5)	6.9 (5.6, 8.3)
Yes	141	2385	6.0 (5.0, 6.9)	5.4 (4.4, 6.4)	55	2261	2.5 (1.8, 3.1)	1.4 (0.8, 2)	122	1946	6.3 (5.2, 7.4)	5.1 (4, 6.2)

*<5% of the data were missing for this variable and values for those with missing values were imputed by assigning the most common value for this variable

**Adjusted for laboratory test performance

*** >60 years old, or reported co-morbidity, or current smoker.

Table S2.

Crude and adjusted** cumulative incidence estimates of SARS-CoV-2 infection in CHASING COVID Cohort Study participants by time period of testing.

Table S3. Crude and adjusted* cumulative incidence estimates of SARS-CoV-2 infection by risk factor and timing of test in CHASING COVID Cohort Study participants

	All unique participants with a serologic test result (Baseline or follow-up) N=4,459				Participants with a serologic test in Period 1 (N=4,235)				Participants with a serologic test in Period 2 (N=3,615)			
	Positive test (Period 1 and/or Period 2)	Total participants	Crude cumulative incidence (95% CI)	Adjusted cumulative incidence (95% CI)	Positive test	Total participants	Crude cumulative incidence (95% CI)	Adjusted cumulative incidence (95% CI)	Positive Test	Total Participants	Crude cumulative incidence (95% CI)	Adjusted cumulative incidence (95% CI)
Total	303	4459	6.8 (6.1, 7.6)	6.3 (5.5, 7.1)	134	4235	3.1 (2.7, 3.7)	2.5 (2.1, 3.1)	258	3615	7.2 (6.3, 8)	6.7 (5.8, 7.5)
Non-pharmaceutical interventions												
Did not use mask	15	217	6.9 (4.2, 11.1)	6.4 (3.6, 10.7)	3	200	1.5 (0.3, 4.3)	0.8 (0, 3.7)	14	274	5.1 (3.1, 8.4)	4.5 (2.5, 7.9)
Attended gatherings	27	299	9 (6.3, 12.8)	8.6 (5.8, 12.4)	9	284	3.1 (1.4, 5.9)	2.5 (0.7, 5.3)	98	1354	7.2 (5.9, 8.7)	6.7 (5.3, 8.2)
Attended Protests	-	-	-	-	-	-	-	-	11	169	6.5 (3.7, 11.3)	6 (3.1, 10.9)
Did not Self-Quarantine	98	1554	6.3 (5.2, 7.6)	5.8 (4.6, 7.1)	28	1481	1.9 (1.2, 2.7)	1.2 (0.5, 2.1)	211	3552	5.9 (5.2, 6.7)	5.3 (4.6, 6.2)
Decreased hand-washing	6	96	6.2 (2.9, 12.9)	5.7 (2.3, 12.5)	2	91	2.1 (0.2, 7.7)	1.4 (0, 7.2)	24	389	6.2 (4.2, 9)	5.7 (3.6, 8.5)
Household factors												
Child in household	77	1204	6.4 (5.1, 7.9)	5.9 (4.5, 7.4)	32	1126	2.8 (2, 4)	2.2 (1.3, 3.4)	62	961	6.4 (5.1, 8.2)	5.9 (4.5, 7.7)
Household crowding												
<4 persons in household	222	3356	6.6 (5.8, 7.5)	6.1 (5.2, 7)	103	3207	3.2 (2.6, 3.8)	2.6 (2, 3.2)	188	2732	6.8 (5.9, 7.9)	6.2 (5.3, 7.4)
4+ persons in single unit	56	834	6.7 (5.2, 8.6)	6.2 (4.6, 8.1)	22	744	2.8 (1.8, 4.2)	2.2 (1.1, 3.6)	48	671	7.1 (5.4, 9.3)	6.6 (4.8, 8.8)
4+ persons in multi unit	23	249	9.2 (6.2, 13.5)	8.7 (5.7, 13.2)	9	236	3.8 (2, 7.1)	3.2 (1.3, 6.6)	20	199	10.1 (6.6, 15)	9.7 (6.1, 14.7)
History of COVID infection and testing												
Thought had COVID	85	629	13.5 (11.1, 16.4)	13.2 (10.7, 16.1)	58	604	9.6 (7.5, 12.2)	9.1 (7, 11.8)	95	675	14.1 (11.6, 16.9)	13.8 (11.2, 16.6)
Known COVID exposure	-	-	-	-	-	-	-	-	27	205	13.2 (9.2, 18.5)	12.8 (8.7, 18.3)
Sought a test	-	-	-	-	-	-	-	-	169	1804	9.4 (8.1, 10.8)	8.9 (7.6, 10.4)
Self-reported positive diagnosis	-	-	-	-	-	-	-	-	82	182	45.1 (38, 52.3)	45.6 (38.3, 53)
Self-reported hospitalization	-	-	-	-	-	-	-	-	8	67	11.9 (6.2, 21.8)	11.5 (5.7, 21.7)
Knew someone who died	33	435	7.6 (5.4, 10.5)	7.1 (4.8, 10.1)	17	416	4.1 (2.5, 6.4)	3.5 (1.8, 5.9)	84	1213	6.9 (5.6, 8.5)	6.4 (5, 8)
No Insurance	55	663	8.3 (6.4, 10.6)	7.8 (5.9, 10.2)	23	616	3.7 (2.5, 5.5)	3.1 (1.8, 4.9)	80	1025	7.8 (6.3, 9.6)	7.3 (5.8, 9.1)
Comorbidities												
Asthma	42	745	5.6 (4.2, 7.5)	5 (3.6, 7)	15	686	2.1 (1.2, 3.5)	1.4 (0.5, 2.9)	35	745	4.7 (3.4, 6.5)	4.1 (2.8, 6)
Heart attack	4	53	7.6 (2.9, 17.8)	7 (2.3, 17.6)	1	50	1.9 (0.1, 10.4)	1.2 (-0.7, 10)	3	53	7.7 (2.6, 20.3)	7.2 (2, 20.1)

Immunosuppression	3	135	2.2 (0.7, 6.3)	1.6 (0, 5.8)	2	129	1.5 (0.2, 5.4)	0.8 (0, 4.8)	3	135	2.8 (0.9, 7.8)	2.1 (0.2, 7.3)
Depression	61	1056	5.7 (4.5, 7.3)	5.1 (3.9, 6.8)	16	995	1.6 (0.9, 2.5)	0.9 (0.2, 1.8)	55	1056	5.2 (4, 6.7)	4.6 (3.4, 6.2)
Diabetes	24	307	7.8 (5.3, 11.4)	7.3 (4.7, 11)	5	286	1.7 (0.5, 3.9)	1 (-0.2, 3.3)	24	307	7.8 (5.3, 11.4)	7.3 (4.7, 11)
HIV	20	214	9.3 (6.1, 13.9)	8.8 (5.5, 13.6)	7	192	3.5 (1.4, 7.1)	2.9 (0.7, 6.6)	17	214	7.9 (5.1, 12.4)	7.4 (4.5, 12)
Other potential risk factors												
Alcohol use**	26	253	10.3 (7.1, 14.6)	9.9 (6.6, 14.3)	9	233	3.7 (1.7, 6.9)	3.1 (1, 6.4)	26	340	7.6 (5.2, 10.9)	7.1 (4.6, 10.5)
Substance use***	-	-	-	-	-	-	-	-	37	607	6.1 (4.4, 8.3)	5.5 (3.8, 7.8)
Received Flu vaccine in 2019	136	1824	7.4 (6.3, 8.7)	6.9 (5.8, 8.2)	70	1751	4 (3.1, 5)	3.4 (2.5, 4.4)	114	1824	7.4 (6.1, 8.8)	6.9 (5.5, 8.3)
PrEP for HIV prevention	-	-	-	-	-	-	-	-	40	383	10.4 (7.7, 13.9)	10 (7.2, 13.6)
Pets in home	-	-	-	-	-	-	-	-	78	1382	5.6 (4.5, 7)	5 (3.9, 6.5)
Public transportation	25	276	9.1 (6.2, 13)	8.6 (5.7, 12.6)	11	258	4.2 (2.1, 7.5)	3.6 (1.4, 7)	87	1053	8.3 (6.7, 10.1)	7.8 (6.2, 9.7)
History of air travel during pandemic	-	-	-	-	-	-	-	-	56	701	7.9 (6.2, 10.2)	7.4 (5.7, 9.8)

Table S3.

Crude and adjusted* cumulative incidence estimates of SARS-CoV-2 infection by risk factor and timing of test in CHASING COVID Cohort Study participants

Table S4. Incidence rates of recent SARS-CoV-2 seroconversion (May 2020-January 2021) by sociodemographic characteristics among CHASING COVID Cohort participants

	No. of seronegative participants in Period 1	No. of incident infections	Total PY*** of follow up	Incidence rate per 100 PY*** (95% CI)	Rate Ratio (95% CI)
Total	3280	145	1562.0	9.3 (7.9, 11.0)	-
Age group*					
18-29	584	33	280.5	11.8 (8.3, 16.7)	1.26 (0.79, 2)
30-39	902	40	428.8	9.3 (6.8, 12.8)	-ref-
40-49	626	31	294.7	10.5 (7.3, 15.1)	1.13 (0.7, 1.8)
50-59	494	20	237.1	8.4 (5.4, 13.2)	0.9 (0.52, 1.54)
60+	674	21	320.8	6.5 (4.2, 10.1)	0.7 (0.41, 1.18)
Gender					
Male	1453	77	711.6	10.8 (8.6, 13.6)	1.34 (0.96, 1.87)
Female	1734	65	803.2	8.1 (6.3, 10.4)	-ref-
Non-binary/Trans	93	3	43.1	7.0 (2.2, 22.0)	0.86 (0.21, 2.43)
Race/Ethnicity*					
White	2218	83	1085.4	7.6 (6.1, 9.5)	-ref-
Hispanic	485	34	210.9	16.1 (11.4, 22.8)	2.11 (1.4, 3.12)
Black	249	15	109.5	13.7 (8.1, 23.1)	1.79 (0.96, 3.13)
Asian	199	7	94.6	7.4 (3.5, 13.7)	0.97 (0.41, 1.99)
Pacific Islander	15	0	7.0	-	
Other	114	6	54.6	11.0 (4.8, 25.0)	1.44 (0.57, 3.1)
Education					
Less than HS	37	2	16.1	12.4 (3.0, 51.7)	1.47 (0.24, 4.98)
HS grad	268	13	115.2	11.3 (6.5, 19.7)	1.34 (0.72, 2.33)
Some college	774	39	353.0	11.0 (8.0, 15.2)	1.31 (0.89, 1.89)
Collge grad	2201	91	1077.6	8.4 (6.8, 10.4)	-ref-
Employment*					
Employed	2005	96	963.3	10.0 (8.1, 12.2)	-ref-
Out of work	387	17	179.5	9.5 (5.8, 15.4)	0.95 (0.55, 1.56)
Homemaker	176	6	77.2	7.8 (3.4, 17.6)	0.78 (0.31, 1.67)
Student	244	12	120.1	10.0 (5.6, 17.9)	1 (0.53, 1.78)
Retired	468	14	221.9	6.3 (3.7, 10.7)	0.63 (0.35, 1.08)
Household income*					
Less than \$35,000	909	45	418.7	10.7 (8.0, 14.5)	1.44 (0.93, 2.26)
\$35-49,999	361	19	168.8	11.3 (7.1, 17.9)	1.51 (0.85, 2.63)
\$50-69,999	484	16	229.3	7.0 (4.2, 11.5)	0.94 (0.51, 1.68)
\$70-99,999	574	30	275.7	10.9 (7.5, 15.7)	1.46 (0.89, 2.38)
\$100,000+	952	35	469.5	7.5 (5.3, 10.4)	-ref-
Setting*					
Urban	1426	54	693.6	7.9 (5.9, 10.2)	-ref-
Suburban	846	36	404.3	8.9 (6.4, 12.4)	1.14 (0.74, 1.74)
Rural	1008	55	464.1	11.9 (9.0, 15.6)	1.52 (1.04, 2.22)
Geographic region*					
Northeast	910	30	447.6	6.7 (4.7, 9.6)	-ref-

Midwest	605	31	285.8	10.8 (7.6, 15.6)	1.62 (0.98, 2.69)
South	934	50	431.5	11.5 (8.7, 15.4)	1.73 (1.1, 2.75)
West	827	34	394.0	8.6 (6.1, 12.2)	1.29 (0.79, 2.12)
US Dep	4	0	2.0	0 (,)	0 (0, 11.75)
Healthcare worker*					
No	2973	129	1416.1	9.1 (7.6, 10.9)	-ref-
Yes	307	16	145.8	11.0 (6.6, 18.1)	1.2 (0.69, 1.98)
Essential worker					
No	2842	116	1356.8	8.5 (7.1, 10.3)	-ref-
Yes	438	29	205.1	14.1 (9.7, 20.6)	1.65 (1.09, 2.46)
High Risk group**					
No	1506	72	722.5	10.0 (7.9, 12.6)	-ref-
Yes	1774	73	839.5	8.7 (6.9, 11.0)	0.87 (0.63, 1.21)

*<5% of the data were missing for this variable and values for those with missing values were imputed by assigning the most common value for this variable

**>60 years old, or reported co-morbidity, or current smoker.

***PY = Person Years

Table S4.

Incidence rates of recent SARS-CoV-2 seroconversion (May 2020-January 2021) by sociodemographic characteristics among CHASING COVID Cohort participants

Table S5. Incidence rates of recent SARS-CoV-2 seroconversion (May 2020-January 2021) by risk factor among CHASING COVID Cohort participants

	No. of seronegative participants in Period 1	No. of incident infections	Total PY of follow up	Incidence rate per 100 PY (95% CI)	Rate Ratio (95% CI)
Total	3280	145	1562	9.3 (7.9, 10.8)	
Household factors					
Household crowding	785	35	259.38	13.5 (9.8, 18.1)	1.61 (1.08, 2.32)
No household crowding	2495	110	1302.62	8.4 (7.1, 10.1)	-ref-
Child in household	932	40	421.65	9.5 (7, 12.6)	1.03 (0.71, 1.47)
No child in household	2348	105	1140.37	9.2 (7.6, 11)	-ref-
No Confirmed case in household member	42	18	34.14	0.5 (0.32, 0.81)	-ref-
Confirmed case in household member	82	25	14.73	1.7 (1.1, 2.5)	3.2 (1.7, 6)
NA	3156	102	1513.15	0.1 (0.05, 0.08)	
Social distancing					
Attended mass gathering(s)	337	16	167.26	9.5 (5.9, 14.9)	1.03 (0.6, 1.7)
Did not attend mass gathering(s)	2943	129	1394.76	9.2 (7.8, 10.8)	-ref-
Indoor dining/bar	1787	102	854.15	11.9 (9.9, 14.3)	1.95 (1.38, 2.83)
No indoor dining/bar	1489	43	707.86	6.1 (4.5, 8.1)	-ref-
Outdoor dining/bar	1896	92	928.21	9.7 (7.8, 11.8)	1.15 (0.85, 1.67)
No outdoor dining/bar	1384	53	633.8	8.4 (6.4, 10.7)	-ref-
Visited place of worship	341	26	158	16.4 (11.5, 21)	1.95 (1.25, 2.93)
Did not visit place of worship	2939	119	1404.02	8.4 (7.1, 10)	-ref-

Visited public park/public pool	2323	103	1131.22	9.1 (7.5, 10.9)	0.94 (0.66, 1.35)
Did not visit public park/pool	957	42	430.8	9.7 (7.3, 12.9)	-ref-
Mask indoor grocery shopping					
N/A (Did not go grocery shopping)	161	8	77.77	10.3 (5.3, 19)	1.17 (0.53, 2.27)
Always	2959	125	1415.05	8.8 (7.4, 10.4)	-ref-
Sometimes	128	12	54.73	21.9 (13, 21.5)	2.49 (1.31, 4.36)
Never	32	0	14.47	0 (0, 20.9)	0 (0, 2.37)
Mask indoor visiting non-household members					
N/A (Did no visit non-household members indoors)	666	27	688.8	3.9 (4.7, 5.6)	-ref-
Always	1047	37	358.54	10.3 (7.5, 13.9)	2.64 (1.6, 4.37)
Sometimes	1081	51	369	13.8 (10.7, 17.7)	3.54 (2.22, 5.69)
Never	438	30	145.66	20.6 (14.8, 27.8)	5.28 (3.11, 8.9)
Mask indoor at work					
N/A (Did not attend indoor workplace)	1595	68	1005.17	6.7 (5.3, 8.4)	-ref-
Always	1293	59	439.83	13.4 (10.5, 16.9)	2 (1.4, 2.81)
Sometimes	282	13	96.81	13.4 (8, 21.6)	2 (1.06, 3.51)
Never	61	5	20.19	24.7 (11.1, 46.5)	3.69 (1.3, 8.46)
Mask indoor at salon/gym					
N/A (Did not attend salon/gym)	2426	106	1290.06	8.2 (6.8, 9.8)	-ref-
Always	699	32	237.52	13.5 (9.7, 18.4)	1.65 (1.09, 2.41)
Sometimes	31	3	9.91	30.3 (10.8, 60.7)	3.7 (0.92, 10.26)
Never	75	4	24.51	16.3 (6.5, 35.2)	1.99 (0.62, 4.91)
Outdoor mask use					
Mask use outdoors	1501	65	716.41	9.1 (7.2, 11.4)	0.96 (0.69, 1.33)
No mask use outdoors	1779	80	845.61	9.5 (7.6, 11.6)	-ref-
Gathered outside in groups >=10					
No	1897	66	898.78	7.3 (5.8, 9.2)	-ref-
Indoors only	224	11	104.58	10.5 (6, 17.8)	1.43 (0.72, 2.64)
Outdoors only	661	35	322.47	10.9 (7.9, 14.7)	1.48 (0.97, 2.22)
Indoors and outdoors	498	33	236.19	14 (10.1, 19)	1.9 (1.24, 2.88)
Movement during the pandemic					
Recent use of public transit					
Avoided or did not use	2628	113	1251.33	9 (7.5, 10.7)	-ref-
Did not avoid	652	32	310.69	10.3 (7.3, 14.2)	1.14 (0.76, 1.67)
Recent Air travel (Aug-Nov)					

Yes	410	29	199.11	14.6 (10.2, 20.1)	1.72 (1.12, 2.55)
No	2870	116	1362.91	8.5 (7.1, 10.1)	-ref-

Table S5.

Incidence rates of recent SARS-CoV-2 seroconversion (May 2020-January 2021) by risk factor among CHASING COVID Cohort participants

Table S6. Characteristics of persons with seroprevalent and seroincident SARS-CoV-2

	All seropositive persons		Observed seroconverters (seronegative in Period 1 and seropositive in Period 2)		Prevalent cases (seropositive on first antibody test)		Seroreversions (seropositive in Period 1, seronegative in Period 2)	
	N	%	N	%	N	%	N	%
Total	303	100	145	47.9	138	45.5	20.0	6.6
Symptoms and clinical outcomes								
Aware of past SARS-CoV-2 infection (footnote)	121	39.9	35	24.1	74	53.6	12.0	60.0
PCR confirmed diagnosis	89	29.4	42	29.0	41	29.7	6.0	30.0
Asymptomatic (footnote details)	83	27.4	37	25.5	39	28.3	7.0	35.0
Mild (symptomatic, but didn't seek care)	190	62.7	87	60.0	87	63.0	16.0	80.0
History of COVID like illness at baseline*	121	39.9	51	35.2	62	44.9	8.0	40.0
Ever had COVID like illness*	209	69.0	105	72.4	93	67.4	11.0	55.0
Nasal discharge, congestion or sneezing	225	74.3	107	73.8	103	74.6	15.0	75.0
Cough/Cough up phlegm	158	52.2	77	53.1	70	50.7	11.0	55.0
Cough up blood	2	0.7	1	0.7	0	0.0	1.0	5.0
Sore throat	140	46.2	71	49.0	61	44.2	8.0	40.0
Itchy eye or eye pain	114	37.6	58	40.0	48	34.8	8.0	40.0
Shortness of breath or chest pain	91	30.0	37	25.5	49	35.5	5.0	25.0
Stomachache, diarrhea, nausea or vomiting	142	46.9	64	44.1	69	50.0	9.0	45.0
Rash	25	8.3	12	8.3	10	7.3	3.0	15.0
Loss of smell	61	20.1	30	20.7	28	20.3	3.0	15.0
Headache	202	66.7	93	64.1	97	70.3	12.0	60.0
Fever, chills or repeated chills	120	39.6	50	34.5	61	44.2	9.0	45.0
Myalgia	106	35.0	58	40.0	45	32.6	3.0	15.0
Ever hospitalized	10	3.3	3	2.1	7	5.1	0.0	0.0
Public health outcomes and testing history								
Ever tested for COVID	195	64.4	92	63.5	91	65.9	12	60.0
Positive SARS-CoV-2 PCR test	97	32.0	43	29.7	48	34.8	6.0	30.0
Isolated from people outside household	93	30.7	42	29.0	45	32.6	6	30.0
Isolated from people within household	41	13.5	23	15.9	16	11.6	2	10.0
Quarantined after contact with COVID	30	9.9	23	15.9	6	4.3	1	5.0
Asked about contacts after COVID diagnosis	54	17.8	29	20.0	24	17.4	1	5.0
Told about contacts with COVID case	23	7.6	10	6.9	8	5.8	5	25.0
Encouraged to get tested because of contact with COVID case	12	4.0	6	4.1	2	1.4	4	20.0
Told to stay home for a period of time	10	3.3	4	2.8	4	2.9	2	10.0

*based on CTSE case definition

Table S6.

Characteristics of persons with seroprevalent and seroincident SARS-CoV-2

Table S7. Additional serologic testing for antibodies to the SARS-CoV-2 spike protein in 392 samples* that were seropositive for antibodies to the SARS-CoV-2 nucleocapsid protein

	Specimens positive by Total Ab in Period 1 or Period 2		Individuals positive by Total Ab in Period 1		Individuals positive by Total Ab in Period 2		Seroconverters (seropositive by Total AB in Period 1, seronegative by Total AB in Period 2)		Seroreverters (seropositive by Total AB in Period 1, seronegative by Total AB in Period 2)	
	N	%	N	%	N	%	N	%	N	%
Total	392	100%	134	100%	258	100%	145	100%	20	100.0
Spike IgG result										
Equivocal	28	7.1%	8	6.0%	20	7.8%	6	4.1%	2	10.0%
Non-Reactive	132	33.7%	31	23.1%	101	39.1%	64	44.1%	13	65.0%
Quantity Not Sufficient	31	7.9%	7	5.2%	24	9.3%	14	9.7%	0	0.0%
Reactive	201	51.3%	88	65.7%	113	43.8%	61	42.1%	5	25.0%
% reactive (excluding QNS**)		63.4%		75.6%		56.8%		51.1%		35.0%

*392 seropositive samples from 303 seropositive participants

**Quantity not sufficient for serologic testing

Table S7.

Additional serologic testing for antibodies to the SARS-CoV-2 spike protein in 392 samples* that were seropositive for antibodies to the SARS-CoV-2 nucleocapsid protein